Biocon Limited has informed the Exchange about Press Release
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon Limited has received Indian regulatory approval (from CDSCO) for its Liraglutide drug substance, while its wholly owned subsidiary Biocon Pharma Limited got approval for the Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge). Liraglutide is the generic version of Victoza, used to treat insufficiently controlled Type 2 Diabetes in adults, adolescents, and children aged 10 and above. This is Biocon's first vertically integrated GLP-1 product in India, approved under the 101 route which recognises approvals from established foreign regulators. The company plans to launch the product in India through its commercialisation partners, targeting a market where diabetes cases exceed 77 million. GLP-1 therapies are expected to be a key future growth driver for Biocon.
Positive for shareholders — this approval opens a new revenue stream in the fast-growing Indian diabetes care market and strengthens Biocon's position in the GLP-1 segment, which management has flagged as a major future growth area. Near-term stock reaction may be modest as the India launch is incremental, but it validates the company's vertical integration strategy for GLP-1 products.